Latest From PharmaMar SA
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- PharmaMar SA
- Senior Management
José María Fernández Sousa-Faro, PhD, Pres. & CEO
Maria Luisa de Francia Caballero, CFO
- Contact Info
Phone: (34) 91 846 6000
Avda. De los Reyes,1
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.